Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry

被引:137
|
作者
Li, JN
Orlandi, R
White, CN
Rosenzweig, J
Zhao, J
Seregni, E
Morelli, D
Yu, YH
Meng, XY
Zhang, Z
Davidson, NE
Fung, ET
Chan, DW
机构
[1] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21231 USA
[3] Natl Canc Inst, I-20133 Milan, Italy
[4] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Ciphergen Biosyst Inc, Fremont, CA USA
关键词
D O I
10.1373/clinchem.2005.052878
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: We previously selected a panel of 3 breast cancer biomarkers (BC1, BC2, and BC3) from serum samples collected at a single hospital based on their collective contribution. to the optimal separation of breast cancer patients and noncancer controls by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). The identities and general applicability of these markers, however, were unknown. In this study, we performed protein expression profiling on samples obtained from a second hospital, included a greater number of ductal carcinoma in situ (DCIS) cases, and performed purification and identification of the 2 confirmed markers. Methods: Using a case-control study design, we performed protein expression profiling on serum samples from the National Cancer Institute (Milan, Italy). The validation sample cohort consisted of 61 women with locally invasive breast cancer, 32 with DCIS, 37 with various benign breast diseases (including 13 atypical), and 46 age-matched apparently healthy women (age range, 44-68 years). Validated biomarkers were purified and identified with serial chromatography, 1-dimensional gel electrophoresis, in-gel ASP-N digestion, peptide mass fingerprinting, and tandem mass peptide sequencing. Results: The BC3 and BC2 expression patterns in this sample set were consistent with the first study sample set. BC3 and BC2 were identified to be complement component C3a(desArg) and a C-terminal-truncated form of C3a(desArg), respectively. Conclusions: Evaluation of biomarkers in independent sample sets can help determine the broader utility of candidate markers, and protein identification permits understanding of their molecular basis. C3a(desArg) appears to lack specificity among patients with benign diseases, limiting its utility as a stand-alone tumor marker, but it may still be useful in a multimarker panel for early detection of breast cancer. (c) 2005 American Association for Clinical Chemistry
引用
收藏
页码:2229 / 2235
页数:7
相关论文
共 50 条
  • [1] Validation of breast cancer biomarkers identified by mass spectrometry
    Diamands, EP
    CLINICAL CHEMISTRY, 2006, 52 (04) : 771 - 772
  • [2] Validation of breast cancer biomarkers identified by mass spectrometry - Respond
    Li, JN
    Zhang, Z
    Chan, DW
    CLINICAL CHEMISTRY, 2006, 52 (04) : 772 - 772
  • [3] Mass spectrometry identified protein biomarkers predicting breast cancer response to chemotherapy
    He, Jianbo
    Gornbein, Jeffrey A.
    Faull, Kym
    Whitelegge, Julian
    Shen, Dejun
    Chang, Helena R.
    CANCER RESEARCH, 2006, 66 (08)
  • [4] Validation of Candidate Serum Ovarian Cancer Biomarkers for Early Detection
    Su, Feng
    Lang, Jennifer
    Kumar, Ashutosh
    Ng, Carey
    Hsieh, Brian
    Suchard, Marc A.
    Reddy, Srinivasa T.
    Farias-Eisner, Robin
    BIOMARKER INSIGHTS, 2007, 2 : 369 - 375
  • [5] Serum proteome mass spectrometry analyses for identification of novel diagnostic biomarkers in breast cancer patients
    Pietrowska, M.
    Behrendt, K.
    Nowicka, E.
    Walaszczyk, A.
    Tarnawski, R.
    Polanska, J.
    Polanski, A.
    Marczak, L.
    Stobiecki, M.
    Widlak, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 188 - 188
  • [6] Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study
    van Winden, Annemieke W. J.
    Gast, Marie-Christine W.
    Beijnen, Jos H.
    Rutgers, Emiel J. Th
    Grobbee, Diederick E.
    Peeters, Petra H. M.
    van Gils, Carla H.
    BMC MEDICAL GENOMICS, 2009, 2
  • [7] Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study
    Annemieke WJ van Winden
    Marie-Christine W Gast
    Jos H Beijnen
    Emiel JTh Rutgers
    Diederick E Grobbee
    Petra HM Peeters
    Carla H van Gils
    BMC Medical Genomics, 2
  • [8] Identifcation of candidate biomarkers for polyarteritis nodosa using data-independent acquisition mass spectrometry
    Ma, Huimin
    Cai, Xintian
    Zhang, Delian
    Zhu, Qing
    Wu, Ting
    Aierken, Xiayire
    Ahmat, Ayguzaili
    Liu, Shasha
    Li, Nanfang
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2025, 17 (01):
  • [9] Validation of Breast Cancer Margins by Tissue Spray Mass Spectrometry
    Chagovets, Vitaliy V.
    Starodubtseva, Natalia L.
    Tokareva, Alisa O.
    Frankevich, Vladimir E.
    Rodionov, Valerii V.
    Kometova, Vlada V.
    Chingin, Konstantin
    Kukaev, Eugene N.
    Chen, Huanwen
    Sukhikh, Gennady T.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) : 1 - 11
  • [10] Identification of serum biomarkers for lung cancer using protein mass spectrometry
    Li, Xin
    Liu, Weixing
    Dong, Baowei
    Sheng, Lin
    Ren, He
    Han, Zhiyu
    Lu, Tong
    Liang, Ping
    MOLECULAR MEDICINE REPORTS, 2012, 6 (03) : 531 - 534